Skip to main content
TipRanks
Go Ultimate75% OFF

Clinuvel Pharmaceuticals (CLVLF) AI Stock Analysis

42 Followers
CLVLF

Clinuvel Pharmaceuticals

(Other OTC:CLVLF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Profitable SCENESSE franchiseA decade of uninterrupted profitability demonstrates a proven commercial model and reduces dependence on unvalidated future products. Record SCENESSE treatment volumes and revenue above AUD 100 million provide an established earnings base that can support continued investment and expansion over the next several years.
Negative Factors
Revenue and margin deteriorationThe return to negative revenue growth and the pronounced gross-margin reset indicate that recent earnings quality is weaker than the historical trend. If this reflects pricing, product mix or cost pressure rather than a temporary fluctuation, it could constrain profitability and reduce funds available for pipeline investment.

Clinuvel Pharmaceuticals (CLVLF) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%CLVLF-33.79%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$249.91M
Dividend Yield
0.75%
Average Volume (3M)
4,097
Price to Earnings (P/E)
10.6
Beta (1Y)
0.06
Revenue Growth
5.04%
EPS Growth
-0.47%
Country
US
Employees
16
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Clinuvel Pharmaceuticals Business Overview & Revenue Model

Company Description

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the...

Clinuvel Pharmaceuticals Earnings Call Summary

Earnings Call Date:Aug 27, 2026(Q4-2026)|% Change Since:-38.39%|Next Earnings Date:Feb 23, 2027
Earnings Call SentimentPositive

The call was predominantly positive, emphasizing a 10th consecutive year of profitability, revenue above AUD 100 million, strong margins, increasing cash reserves, a debt-free balance sheet, continued R&D investment, and multiple strategic and clinical catalysts. The main challenges were moderated U.S. sales due to competitor trial programs, currency translation effects, a long vitiligo development timeline, continued FDA engagement requirements, and PhotoCosmetics not yet being ready for launch.

Positive Updates

Tenth Consecutive Year of Profitability
CLINUVEL delivered its 10th consecutive year of profits, maintaining a profitable business model in the life sciences sector.

Negative Updates

Moderation in U.S. Sales and Treatment Volumes
U.S. sales and treatment numbers moderated during the financial year, which management attributed to competitors offering free product through clinical trial programs.

Company Guidance

Management said that, on average, over the next 5 years, expenditure will be about AUD 55 million each year; it is guiding the business by an 83% gross profit margin and 36% net profit margin, and expects EPP growth to be “probably not double digit, but single digit.” The CUV105 top-line results and start of the CUV107 study are both expected in Q4, with CUV107 planned to run for approximately 2 years from recruitment in November 2026 and readout expected in 2029. The target is 190 trained accredited centers by 2027, while vitiligo treatment is assessed at 7 and 12 implants per patient as a one-off treatment, with 1 to 2 injections per year as maintenance; NEURACTHEL is planned to be filed with the EMA in the second half of this calendar year, followed by the FDA, with an average turnaround time of 12 to 16 months after filing a dossier.

Clinuvel Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CLVLF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:BIOAU:BIO69NeutralAUD 79.84M20.1946.74%―29.68%1520.00%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:PYCAU:PYC50NeutralAUD 1.61B-27.33-10.31%――39.63%
AU:ACRAU:ACR47NeutralAUD 6.12M-7.14-45.29%―290.25%92.05%
AU:SPLAU:SPL44NeutralAUD 200.41M-23.98-42.35%―145.32%25.75%
AU:BOTAU:BOT38UnderperformAUD 27.63M-0.28-118.74%―499.47%31.20%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%CLVLFAU:ACRAU:SPLAU:PYCAU:BOTAU:BIODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CLVLF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CLVLFClinuvel Pharmaceuticals Limited4.71-2.40-33.69%
AU:ACRAcrux Limited0.01-0.00-33.33%
AU:SPLStarpharma Holdings Limited0.420.0410.82%
AU:PYCPYC Therapeutics Limited1.650.2719.90%
AU:BOTBotanix Pharmaceuticals Limited0.01-0.11-91.30%
AU:BIOBiome Australia Ltd0.32-0.07-17.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.